12/12-2022 - Marie-Caroline DIEU-NOSJEAN : Tumor-associated Tertiary lymphoid structures as a key “headquarters” for the development of protective immune response in NSCLC patients

LES LUNDIS DE SAINT-ANTOINE

Bâtiment Kourilsky - 13h–14h

Salle des Conférences (Rez de Chaussée),

184 rue du Faubourg Saint-Antoine, Paris

***

LUNDI 12 DECEMBRE 2022

Tumor-associated Tertiary lymphoid structures as a key “headquarters”
for the development of protective immune response in NSCLC patients

Marie-Caroline DIEU-NOSJEAN

Cimi, Sorbonne Université UMRS1135, Inserm U1135, Paris

invitée par Equipe de Alex DUVAL (Equipe DUVAL (alex.duval@inserm.fr))

***

The presence of tertiary lymphoid structures (TLS) in the tumor microenvironment is associated with better clinical outcome in many cancers. In non-small cell lung cancer (NSCLC), we have showed that a high density of B cells within TLS (TLS-B cells) is positively correlated with tumor antigen-specific antibody responses and increased intratumor CD4+ T cell clonality. Little is known about the interaction between effector B cells and other T cell subsets such as CD8+ T cells in human tumors.
Plasma cells (PC) have been studied mainly for their unique capacity to secrete antibodies. Here, we investigated whether PC subsets affect the prognosis of NSCLC patients by cellular interaction with the immune microenvironment knowing that TLS are a key site for the differentiation of B cells into effector PC.
As seen in TLS, high densities of IgA+ and IgG+ PC are associated with long-term survival of NSCLC patients. Interestingly, IgA+ and IgG+ PC cluster with proliferating CD8+ T cells, a phenomenon that has been reproduced ex vivo from autologous cells freshly isolated from NSCLC patients with high densities of TLS, PC subsets, and CD8+ T cells. IgAhigh IgGhigh CD8high patients had the best clinical outcomes, while patients with few PC had dramatically poorer survival, even with infiltrate high in CD8+ T cells.
These data suggest that TLS may be a key site for local differentiation of both CD8+ T cells and PC; the latter contribute to an effective antitumor immune response by amplifying the CD8+ T-cell response.

Afin d'assister à cette conférence vous pourrez vous connecter sur le lien teams suivant :

Rejoindre à partir de votre ordinateur, de l'application mobile ou de l'appareil de la salle
Cliquez ici pour rejoindre la réunion
ID de la réunion : 342 678 313 179
Code secret : mZteDi
Télécharger Teams | Rejoindre sur le web
Rejoindre avec un appareil de visioconférence
81292735@t.plcm.vc
ID de vidéoconférence : 123 084 587 7